Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
AACR: Regeneron's multiple myeloma drug shows staying power
Regeneron’s multiple myeloma drug, which was recently accepted for FDA priority review, is showing durability in the latest data from a phase 1/2 test
Annalee Armstrong
Apr 7, 2024 4:00pm
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Mar 29, 2024 5:00am
Takeda drops cancer candidates amid shifting treatment landscape
Feb 2, 2024 5:33am
Regeneron's 'best-in-class' myeloma drug spurs 100% side effects
Dec 7, 2023 7:00am
C4 culls phase 1/2 cancer program after efficacy fail
Nov 1, 2023 11:29am
AbbVie drops Harpoon’s BCMA drug, ending dream of $200M payday
Sep 14, 2023 10:21am